AVEO Pharmaceuticals Inc (AVEO)

0.59
0.00 0.78
NASDAQ : Health Care
Prev Close 0.59
Open 0.58
Day Low/High 0.58 / 0.60
52 Wk Low/High 0.82 / 2.59
Volume 220.71K
Avg Volume 521.10K
Exchange NASDAQ
Shares Outstanding 110.36M
Market Cap 66.22M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AVEO Announces Milestone Payment From CANbridge For AV-203

AVEO Announces Milestone Payment From CANbridge For AV-203

AVEO Oncology (NASDAQ:AVEO) today announced receipt of a $500,000 milestone payment from CANbridge Life Sciences Ltd.

AVEO Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares

AVEO Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced the closing of its previously announced underwritten public offering of 34,500,000 shares of common stock, including the exercise in full by the underwriter of its...

AVEO Announces Pricing Of $15.0 Million Public Offering Of Common Stock

AVEO Announces Pricing Of $15.0 Million Public Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price to the public of $0.

AVEO Announces Proposed Offering Of Common Stock

AVEO Announces Proposed Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

AVEO Reports Full Year 2016 Financial Results And Provides Business Update

AVEO Reports Full Year 2016 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2016 and provided a business update.

AVEO Announces First Patient Dosed In Phase 1/2 TiNivo Trial Of Tivozanib And Opdivo® (nivolumab) In Advanced RCC

AVEO Announces First Patient Dosed In Phase 1/2 TiNivo Trial Of Tivozanib And Opdivo® (nivolumab) In Advanced RCC

AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb's anti-PD-1 therapy, Opdivo®...

AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review

AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review

AVEO Oncology (NASDAQ:AVEO) today announced that its pivotal, Phase 3 TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell...

AVEO Announces Clinical And Regulatory Updates For Tivozanib

AVEO Announces Clinical And Regulatory Updates For Tivozanib

AVEO Oncology (NASDAQ:AVEO) today announced clinical and regulatory updates for its lead drug candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

AVEO To Present At The 19th Annual BIO CEO & Investor Conference

AVEO To Present At The 19th Annual BIO CEO & Investor Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.

AVEO Announces Submission Of Responses To The EMA Day 120 List Of Questions For Marketing Authorization Application For Tivozanib In Renal Cell Carcinoma

AVEO Announces Submission Of Responses To The EMA Day 120 List Of Questions For Marketing Authorization Application For Tivozanib In Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced that its development partner, EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, has submitted its responses to the European...

AVEO To Present At The 28th Annual Piper Jaffray Healthcare Conference

AVEO To Present At The 28th Annual Piper Jaffray Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 28 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 3:30 PM Eastern...

AVEO Oncology Reports Third Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology Reports Third Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2016.

AVEO To Present At The 15th Annual BIO Investor Forum

AVEO To Present At The 15th Annual BIO Investor Forum

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 15th Annual BIO Investor Forum on Wednesday, October 19, 2016 at 11:30 AM Pacific Time.

AVEO Oncology Announces Proposed Settlement And Settlement Hearing In 2014 Stockholder Litigation

AVEO Oncology Announces Proposed Settlement And Settlement Hearing In 2014 Stockholder Litigation

AVEO Oncology (NASDAQ:AVEO) today announced that a settlement hearing will be held on December 19, 2016 at 3:00 p.

AVEO To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

AVEO To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 18 th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at...

AVEO Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb's Opdivo® (nivolumab) In Advanced Renal Cell Carcinoma

AVEO Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb's Opdivo® (nivolumab) In Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced the initiation of a clinical evaluation of AVEO's oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with...

AVEO Oncology Reports Second Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology Reports Second Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2016.

AVEO To Present At The 2016 JMP Securities Life Science Conference

AVEO To Present At The 2016 JMP Securities Life Science Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.

AVEO Announces Dosing Of First Patient In The Pivotal Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma

AVEO Announces Dosing Of First Patient In The Pivotal Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects...

AVEO Announces Closing Of Private Placement And Amended Term Loan To Fund Pivotal TIVO-3 Trial And Combination PD-1 Trial Of Tivozanib In Renal Cell Cancer

AVEO Announces Closing Of Private Placement And Amended Term Loan To Fund Pivotal TIVO-3 Trial And Combination PD-1 Trial Of Tivozanib In Renal Cell Cancer

AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock, at...

AVEO Announces $17 Million Private Placement

AVEO Announces $17 Million Private Placement

AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and...

AVEO Oncology Reports First Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology Reports First Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016.

AVEO Announces Filing Of Provisional Patent Applications For AV-353, A Notch 3-Specific Inhibitor Antibody For PAH

AVEO Announces Filing Of Provisional Patent Applications For AV-353, A Notch 3-Specific Inhibitor Antibody For PAH

AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company's potent...

AVEO And CANbridge Life Sciences Announce Exclusive Licensing Agreement For AV-203 Outside Of North America

AVEO And CANbridge Life Sciences Announce Exclusive Licensing Agreement For AV-203 Outside Of North America

AVEO Oncology (NASDAQ:AVEO) and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, today announced an exclusive collaboration and license agreement in...

AVEO Oncology Reports Full Year 2015 Financial Results And Provides Business Update

AVEO Oncology Reports Full Year 2015 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2015 and provided a business update.

AVEO To Present At The 28th Annual ROTH Conference

AVEO To Present At The 28th Annual ROTH Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 9:00 a.

EUSA Pharma And AVEO Announce Submission Of Marketing Authorization Application For Tivozanib In Advanced Renal Cell Carcinoma

EUSA Pharma And AVEO Announce Submission Of Marketing Authorization Application For Tivozanib In Advanced Renal Cell Carcinoma

EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ:AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for...

AVEO Announces Acceptance Of Registration Dossier For Tivozanib In RCC By The Ministry Of Health Of The Russian Federation

AVEO Announces Acceptance Of Registration Dossier For Tivozanib In RCC By The Ministry Of Health Of The Russian Federation

AVEO Oncology (NASDAQ:AVEO) today announced that a registration dossier seeking to obtain marketing authorization of tivozanib as a first line treatment of advanced renal cell carcinoma ("RCC") has been accepted by the...